5 October 2020 - The US FDA has announced historic low rates for the fiscal year 2021 fees to use its three priority review voucher programs.

For the upcoming fiscal year, the rate to use a material threat medical countermeasure (MCM) priority review voucher (PRV) is an all-time low $1,360,879. 

The PRV rate is the same for the rare paediatric disease and rare tropical disease voucher programs, according to Federal Register announcements.

Read Regulatory Affairs Professional Society article